PharmaGossipAtLast

  • Subscribe to our RSS feed.
  • Twitter
  • StumbleUpon
  • Reddit
  • Facebook
  • Digg

Sunday, September 15, 2013

Petition by Professor David Healy - please sign if you agree

Posted on 4:01 AM by Unknown

Let us see Drug Data! Drug hazards are not “trade secrets”!

Drug companies maximize the sales of new drugs by hyping their benefits while downplaying significant risks. In 2010 the European Medicines Agency began releasing patient-level data from the clinical trials used to approve new medicines in Europe – a development hailed by American, and European researchers and researchers around the world as a major step towards drug safety.

This process has been shut down by a lawsuit taken by two American corporations – AbbVie, makers of Humira, the number one selling medication in the world with projected sales of $10 billion in 2013; and InterMune, whose pulmonary-fibrosis drug Esbriet has recently been approved in Europe at a cost of over $40,000 per year.

AbbVie and InterMune have filed suit to deny access to the data from their trials on the benefits and harms of these drugs, claiming these vital facts are “trade secrets” whose release would harm their profits. Their action has led to the shutdown of the entire public-access program, leaving millions of patients worldwide, and their doctors, in the dark.

We call on AbbVie and InterMune to drop their European Union lawsuit and release all patient level data on Humira, Esbriet and their other products. Vital data on drug safety should never be hidden as a “trade secret.” By copying this petition to President Barack Obama and members of his Cabinet we call on them to ensure that meaningful public access to clinical trial data becomes the policy of the FDA and is written into any international trade agreements governing the sale of prescription drugs and devices.

Copies to: 
President Barack Obama; 
Margaret Hamburg, M.D., Commissioner, Food & Drug Administration; 
Secretary General Ban Ki Moon, United Nations; 
World Health Organization Director Dr Margaret Chan.

To: 
Richard Gonzalez, c/o Gregory Miley, Group Head, External Communications, AbbVie 
Daniel Welch, c/o Jim Goff, VP Corporate Communications
Please drop your legal action blocking access to EMA clinical trial data. 

Sincerely, 
[Your name]


http://www.change.org/petitions/richard-gonzalez-of-abbvie-and-daniel-w

elch-of-intermune-drop-your-legal-

action-blocking-access-to-ema-clinical-trial-data?utm_source=guides&utm_medium=email&utm_

campaign=petition_lonely


Email ThisBlogThis!Share to XShare to FacebookShare to Pinterest
Posted in | No comments
Older Post Home

0 comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Popular Posts

  • Beautiful Barcelona! - Gedeon Richter ruled in breach of ABPI code
    LYNNE TAYLOR Gedeon Richter (UK) has breached the Association of the British Pharmaceutical Industry (ABPI) Code of Practice, and has brough...
  • GlaxoChinaGate contd. - Bwaaa!
    China Drug Probe 'Unfair,' Euro Group Says Thu, 09/05/2013 - 8:30am Foreign companies believe they are unfairly being singled out fo...
  • Another day, another J&J recall ... Mold found in schizophrenia drug forces Johnson & Johnson recall
    By  Bloomberg News  on September 11, 2013 at 5:25 PM, updated  September 11, 2013 at 5:27 PM Johnson & Johnson has recalled 5,000 vials ...
  • AllTrials Update
    Dear Friends Support for AllTrials around the world is growing and we need to keep it that way as we reach some crucial debates. The Europea...
  • Hurrah!
    Press Release 11 September 2013 FOR IMMEDIATE RELEASE The HRA is now implementing its plans for ensuri...
  • Advertisement
    The book addresses, in great, evidence-based detail, a general system failure caused by widespread crime, corruption, bribery and impotent d...
  • Of pigs and penicillin
    Extended Withdrawal Needed to Avoid Penicillin G Residues News US - A minimum 51-day withdrawal is necessary if penicillin G is used in pigs...
  • The Lancet has formally retracted the Jikei Heart Study paper, originally published in 2007
    . The retraction had been widely anticipated for more than a month, after a series of news reports in Japan made it clear that the long-simm...
  • Wrigley holds off on caffeinated gum as FDA reviews caffeine
    By Melissa Healy 7:54 p.m. EDT, May 9, 2013 Less than a week after the Food and Drug Administration announced that it would investigate the ...
  • Petition by Professor David Healy - please sign if you agree
    Let us see Drug Data! Drug hazards are not “trade secrets”! Drug companies maximize the sales of new drugs by hyping their benefits while do...

Categories

  • Abbott (1)
  • alltrials (1)
  • alosetron (1)
  • AstraZeneca (1)
  • Baxter (1)
  • big pharma (2)
  • bribery (7)
  • Champix (1)
  • chantix (1)
  • china (7)
  • Clinical Trails (1)
  • Clinical Trial (1)
  • corruption (5)
  • Dan Markingson (1)
  • Dan Markingson Death (1)
  • diabetes (2)
  • Diovan (1)
  • EFPIA (1)
  • glaxo (11)
  • Glaxo China bribery corruption (1)
  • gsk (7)
  • hongbao (1)
  • insurance (1)
  • Januvia (1)
  • johnson and johnson (1)
  • Lotronex (1)
  • Mefloquine (1)
  • Mental Health (1)
  • Merck (2)
  • Novartis (1)
  • pancreas (1)
  • pfizer (1)
  • pharma (1)
  • pharmaceuticals (1)
  • PhRMA (1)
  • quetiapine (1)
  • Sanofi (2)
  • scandal (1)
  • seroquel (1)
  • side effects (1)
  • suvorexant (1)
  • ucb (1)
  • Valsartan (1)
  • Zaltrap (1)

Blog Archive

  • ▼  2013 (300)
    • ▼  September (40)
      • Petition by Professor David Healy - please sign if...
      • Advertisement
      • 1boringoldman explains data transparency
      • AllTrials Update
      • Ketamine, A Darling of the Club Scene, Inspires Ne...
      • Shouldn’t Hip & Knee Replacements Come With Warran...
      • Wise words
      • GlaxoChinaGate contd. - German drug giant Bayer la...
      • Winning friends
      • Richard Smith: Is the pharmaceutical industry like...
      • Another day, another J&J recall ... Mold found in ...
      • Hurrah!
      • Pain drugs will need new warnings to alert patient...
      • Implementation of a publication strategy in the co...
      • GlaxoChinaGate contd. - GSK affirms China plans, d...
      • Dementia campaign could lead to over-diagnosis, sa...
      • Of Conflicts and Clinical Trials: Researchers Repo...
      • Slumdog Clinical Trials contd - Kenyan patients be...
      • Beautiful Barcelona! - Gedeon Richter ruled in bre...
      • Now I wonder how GSK will find the cash to pay for...
      • GlaxoChinaGate contd. - Rick Tang explains China's...
      • Deaths soar as Britain turns into nation of prescr...
      • Another J&J recall - Infant Motrin due to plastic...
      • GlaxoChinaGate contd. Now US prosecutors add China...
      • The Lancet has formally retracted the Jikei Heart ...
      • A Glut of Antidepressants
      • GlaxoChinaGate contd. - Bwaaa!
      • Takeda Put Actos Sales Ahead of Safety, Lawyer Tel...
      • It's never good when authorities talk openly of im...
      • Of pigs and penicillin
      • Riots, Rage, and Resistance: A Brief History of Ho...
      • GlaxoChinaGate contd. Reforms urged for pharma ind...
      • FDA probe Gilenya
      • GlaxoChinaGate contd.. - now HR are spotlighted. C...
      • Richard Smith, Former Editor-in-Chief, BMJ reviews...
      • Peter C Gøtzsche, Professor, Director, MD, DrMedSc...
      • Wrigley holds off on caffeinated gum as FDA review...
      • Ooh la la
      • Deadly Medicines and Organized Crime by Peter Gøtz...
      • You are welcome
    • ►  August (70)
    • ►  July (104)
    • ►  June (81)
    • ►  May (5)
Powered by Blogger.